|
MYL5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.93350002675174E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.87729995174635E-09 |
| Normal-vs-Stage2 |
1.103140E-03 |
| Normal-vs-Stage3 |
1.17929999998712E-06 |
| Normal-vs-Stage4 |
1.04880000018071E-07 |
| Stage1-vs-Stage2 |
3.772000E-01 |
| Stage1-vs-Stage3 |
7.308000E-01 |
| Stage1-vs-Stage4 |
3.743200E-01 |
| Stage2-vs-Stage3 |
5.360200E-01 |
| Stage2-vs-Stage4 |
1.377630E-01 |
| Stage3-vs-Stage4 |
3.141800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.82270018259601E-10 |
| Normal-vs-AfricanAmerican |
9.158500E-04 |
| Normal-vs-Asian |
7.68570000000413E-05 |
| Caucasian-vs-AfricanAmerican |
6.011400E-01 |
| Caucasian-vs-Asian |
4.895400E-01 |
| AfricanAmerican-vs-Asian |
9.931800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.53010000000431E-05 |
| Normal-vs-Female |
6.29129970342035E-10 |
| Male-vs-Female |
2.290200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.49100000004887E-06 |
| Normal-vs-Age(41-60Yrs) |
1.93589999586408E-09 |
| Normal-vs-Age(61-80Yrs) |
2.03119999997448E-06 |
| Normal-vs-Age(81-100Yrs) |
2.847200E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.591000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.876800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.679200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.170000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.181600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.109600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.325400E-01 |
| Classical-VS-Follicular |
6.533900E-02 |
| Classical-VS-Other |
2.829800E-01 |
| Classical-VS-Normal |
1.95339966424513E-10 |
| Tall-VS-Follicular |
6.647000E-01 |
| Tall-VS-Other |
2.204200E-01 |
| Tall-VS-Normal |
9.038200E-03 |
| Follicular-VS-Other |
3.076300E-02 |
| Follicular-VS-Normal |
1.096340E-03 |
| Other-VS-Normal |
4.600700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.4029000000001E-05 |
| Normal-vs-N1 |
3.967200E-04 |
| N0-vs-N1 |
2.182200E-01 |
|
|
